Novartis AG (NVS – Q4FY19 & FY19) – Launched 5 new potential blockbusters in 2019.

in , on March 4, 2020

Novartis’s key growth drivers were mainly Cosentyx,Entresto and Zolgensma for the Pharmaceuticals Business Unit and Promacta/Revolade, Kisqali and Lutathera for the Oncology Business Unit.The company acquired “The Medicines Company”, adding inclisiran a potentially transformative cholesterol-lowering therapy. NVS also acquired Xiidra, strengthening ophthalmic pharmaceuticals portfolio.

Executive Summary

Financial Statements

– Income Statement and Forecast
– Balance Sheet
– Cash Flow
– Q4FY19 Results – Overview
– FY19 Results – Overview
– Q4FY19 – Segment Performance
– Q4FY19 – R&D Update
– FY20 Guidance and Conclusion..
– IFRS to Non-IFRS reconciliation

Historical Performance

– Key Ratios
– Profitability Ratios, Asset Turnover Ratio, Growth Ratio
– DuPont Analysis
– Return on Invested Capital
– Per Share Items and Key Ratios
– Key Cash Flow Items
– P/E Band

 Product Performance and Key Developments

– Ownership
– Competition
– Key Developments

Valuation and Consensus Performance

– Relative Valuation
– Analyst Recommendations

Market Price Performance

CrispIdea Coverage Chart

Release Information

  • Released
    :

    March 4, 2020

  • Last Updated
    :

    March 9, 2020